文献速递主动脉疾病外周动脉疾病

E-liac支架系统治疗单侧或双侧主髂动脉或髂动脉瘤三十天与一年结局的前瞻性多中心注册研究:PLIANTII研究

A Prospective, Multicentre Registry on Thirty Day and One Year Outcomes of the E-liac Stent Graft System in Patients with Unilateral or Bilateral Aorto-iliac or Iliac Aneurysms: The PLIANTII Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-02-20

PLIANTII为前瞻性、观察性、非随机、多中心研究,2018年9月至2023年9月纳入30个欧洲中心295例择期治疗髂动脉瘤患者,236例合并肾下腹主动脉瘤。主要终点12个月达91.8%,30天无死亡,12个月死亡7例,技术成功93.1%,临床成功91.2%。作者认为E-liac支架系统治疗安全且技术及临床成功率高。

要点

  • 295例患者中主要终点(无I/III型内漏且EIA与IIA通畅)12个月达91.8%。
  • 30天无死亡,12个月死亡7例,Kaplan-Meier估计12个月生存率96.7±1.2%。
  • 12个月内再干预率12.9%,免于E-liac相关再干预率91.3±1.8%。

核心结论

  • PLIANTII研究一年数据显示,E-liac支架系统治疗安全,技术成功率和临床成功率高。

研究设计与样本

  • PLIANTII为前瞻性、观察性、非随机、多中心研究,2018年9月至2023年9月在30个欧洲中心纳入295例择期治疗髂动脉瘤患者,其中236例同时治疗肾下腹主动脉瘤,随访至12个月。

主要发现

  • 主要终点(12个月随访时E-liac植入侧无I或III型内漏且髂外动脉和髂内动脉通畅)在91.8%的患者中达到。
  • 30天内无死亡,12个月时死亡7例,Kaplan-Meier估计至12个月随访生存率为96.7±1.2%。
  • 出院或30天技术成功率为93.1%,12个月临床成功率为91.2%。
  • 30天内再干预率5.4%,12个月内再干预率12.9%,Kaplan-Meier估计至12个月免于E-liac相关再干预率为91.3±1.8%。
  • 出院或30天随访时髂外动脉一期通畅率97.6%(284/291),髂内动脉96.2%(280/291);Kaplan-Meier估计至12个月免于闭塞率髂外动脉94.5±1.6%,髂内动脉94.7±1.5%。

临床怎么用

  • 作者认为E-liac支架系统治疗髂动脉瘤安全,技术成功率和临床成功率高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to prospectively evaluate the real world outcomes of the E-liac stent graft system used to electively treat common iliac artery aneurysms, either unilaterally or bilaterally. METHODS: PLIANTII is a prospective, observational, non-randomised, multicentre study. The E-liac stent graft system was implanted for the treatment of iliac artery aneurysms in 295 patients across 30 European centres between September 2018 and September 2023, with 236 patients also treated for a concomitant infrarenal abdominal aortic aneurysm. The endpoints, including clinical outcomes, are reported up to the twelve month follow up. The primary endpoint was a composite of freedom from type I or III endoleak plus patency of the external (EIA) and internal iliac arteries (IIA) on the E-liac implantation side(s) at the twelve month follow up. Technical success was defined as successful access and deployment of the stent graft without surgical conversion, death, type I or III endoleak, or graft limb occlusion, assessed at discharge or 30 days. Clinical success, evaluated at twelve months, also included the absence of stent graft infection and iliac aneurysm rupture. RESULTS: Two hundred and ninetyfive consecutive patients (95.6% male; mean age 72.7 years) were included. The primary endpoint was achieved in 91.8%. No death was recorded within 30 days of implantation, and seven deaths had occurred at twelve months. The Kaplan-Meier estimated survival rate up to the twelve month follow up visit was 96.7 ± 1.2%. Technical success at discharge or 30 days was achieved in 93.1% of patients, while clinical success at twelve months was achieved in 91.2%. There were 5.4% re-interventions within 30 days and 12.9% within twelve months. The Kaplan-Meier estimated freedom from E-liac related re-intervention up to the twelve month follow up visit was 91.3 ± 1.8%. The primary patency rate at discharge or 30 day visit was 97.6% (284/291) for the EIA and 96.2% (280/291) for the IIA, whereas Kaplan-Meier estimated freedom from occlusion up to twelve months was 94.5 ± 1.6% for the EIA and 94.7 ± 1.5% for the IIA. CONCLUSION: The one year data from the PLIANTII study show that treatment with the E-liac stent graft system is safe and results in good technical and clinical success rates.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Oberhuber A, Deglise S, Richter O, et al. A Prospective, Multicentre Registry on Thirty Day and One Year Outcomes of the E-liac Stent Graft System in Patients with Unilateral or Bilateral Aorto-iliac or Iliac Aneurysms: The PLIANTII Study. Eur J Vasc Endovasc Surg. 2025. PMID: 39986435. doi:10.1016/j.ejvs.2025.02.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。